Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

NCT03116529 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

22

Enrollment

OTHER

Sponsor class

Stopped Limited Accrual

Conditions

Soft Tissue Sarcoma

Interventions

COMBINATION_PRODUCT: Combination Radiation, Immunotherapy, Surgery

Sponsor

University of Maryland, Baltimore

Collaborators

[object Object]
[object Object]
[object Object]